About Galectin-9B
Galectin-9B (LGALS9B) is a protein
from Homo sapiens identified by UniProt accession
Q3B8N2, 356 residues long.
MolForge cross-references it against 0 known binders and
140 disease associations.
Target properties
| Protein name | Galectin-9B |
|---|
| UniProt accession | Q3B8N2 |
|---|
| Gene | LGALS9B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 356 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (140)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.41
- mean reticulocyte volume · score 0.33
- mean corpuscular hemoglobin concentration · score 0.32
- mean platelet volume · score 0.19
- Immature Reticulocyte Fraction Measurement · score 0.13
- reticulocyte count · score 0.11
- heel bone mineral density · score 0.09
- Familial hemophagocytic lymphohistiocytosis · score 0.05
- Felty's syndrome · score 0.05
- immunodeficiency 72 with autoinflammation · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q3B8N2-F1 | alphafold | PREDICTED | 84.50 | — |
Amino-acid sequence (356 residues)
MAFSGSQAPY LSPAVPFSGT IQGGLQDGFQ ITVNGAVLSS SGTRFAVDFQ TGFSGNDIAF HFNPRFEDGG YVVCNTRQKG RWGPEERKMH MPFQKGMPFD LCFLVQSSDF KVMVNGSLFV QYFHRVPFHR VDTISVNGSV QLSYISFQNP RTVPVQPAFS TVPFSQPVCF PPRPRGRRQK PPSVRPANPA PITQTVIHTV QSASGQMFSQ TPAIPPMMYP HPAYPMPFIT TIPGGLYPSK SIILSGTVLP SAQRFHINLC SGSHIAFHMN PRFDENAVVR NTQINNSWGS EERSLPRKMP FVRGQSFSVW ILCEAHCLKV AVDGQHVFEY YHRLRNLPTI NKLEVGGDIQ LTHVQT
Explore Galectin-9B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets